Search Results - "Kumar, Shaji"

Risk stratification and early intervention in smoldering multiple myeloma.

Authors: Sra, Manraj Singh Kumar, Shaji

Source: Leukemia & Lymphoma. Jan2026, Vol. 67 Issue 1, p55-63. 9p.

Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future.

Authors: Zanwar, Saurabh Kumar, Shaji

Source: Leukemia & Lymphoma. Apr2025, Vol. 66 Issue 4, p573-583. 11p.

Multiple Myeloma

Authors: Kumar, Shaji

Resource Type: eBook.

Subjects: Multiple myeloma

Categories: MEDICAL / Oncology / General

Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis.

Authors: Voorhees, Peter M. Kumar, Shaji Usmani, Saad Z. et al.

Source: Annals of Hematology. Dec2025, Vol. 104 Issue 12, p6263-6274. 12p.

Monoclonal Gammopathy of Undetermined Significance.

Authors: Rajkumar, S. Vincent Kumar, Shaji

Source: New England Journal of Medicine. 10/2/2025, Vol. 393 Issue 13, p1315-1326. 12p.

BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.

Authors: Rees, Matthew James Kumar, Shaji

Source: Leukemia & Lymphoma. Mar2024, Vol. 65 Issue 3, p287-300. 14p.

Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study.

Authors: Kumar, Shaji Dispenzieri, Angela Bhutani, Divaya et al.

Source: Amyloid. Sep2023, Vol. 30 Issue 3, p268-278. 11p.

Oral Therapies for Multiple Myeloma.

Authors: Singhal, Sachi Kumar, Shaji

Source: touchREVIEWS in Oncology & Haematology. 2022, Vol. 18 Issue 2, p139-151. 13p.

Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma.

Authors: Zanwar, Saurabh Kumar, Shaji

Source: Leukemia & Lymphoma. Dec 2021, Vol. 62 Issue 13, p3087-3097. 11p.

3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.

Authors: Chim, Chor Sang Kumar, Shaji Wong, Vincent Kai Chung et al.

Source: Hematology. Dec 2021, Vol. 26 Issue 1, p652-655. 4p.

Front‐line treatment patterns in multiple myeloma: An analysis of U.S.‐based electronic health records from 2011 to 2019.

Authors: Kumar, Shaji Williamson, Mellissa Ogbu, Uzor et al.

Source: Cancer Medicine. Sep2021, Vol. 10 Issue 17, p5866-5877. 12p.

Autologous stem cell transplantation for multiple myeloma patients whose myeloma‐defining event was SLiM.

Authors: Vaxman, Iuliana Kumar, Shaji Cohen, Inbar et al.

Source: British Journal of Haematology. Feb2025, Vol. 206 Issue 2, p607-614. 8p.

THE AUTHORS REPLY.

Authors: Rajkumar, S. Vincent Kumar, Shaji

Source: New England Journal of Medicine. 1/1/2026, Vol. 394 Issue 1, p101-102. 2p.

Change of guard at Amyloid – a tribute to outgoing Editor in Chief, Professor Per Westermark.

Authors: Kumar, Shaji¹ (AUTHOR) kumar.shaji@mayo.edu

Source: Amyloid. Dec2025, Vol. 32 Issue 4, p301-302. 2p.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Authors: Kumar, Shaji Durie, Brian Nahi, Hareth et al.

Source: Leukemia & Lymphoma. Jan2019, Vol. 60 Issue 1, p163-171. 9p.

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

Authors: Ramakrishnan, Vijay Kumar, Shaji

Source: Leukemia & Lymphoma. Nov2018, Vol. 59 Issue 11, p2524-2534. 11p.

Minimal residual disease analysis in myeloma - when, why and where.

Authors: Yanamandra, Uday Kumar, Shaji K.

Source: Leukemia & Lymphoma. Aug2018, Vol. 59 Issue 8, p1772-1784. 13p.

Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer.

Authors: Muchtar, Eli Kumar, Shaji K. Magen, Hila et al.

Source: Leukemia & Lymphoma. Feb2018, Vol. 59 Issue 2, p288-299. 12p.

Clinical course and prognosis of non-secretory multiple myeloma.

Authors: Chawla, Sagar S. Kumar, Shaji K. Dispenzieri, Angela et al.

Source: European Journal of Haematology. Jul2015, Vol. 95 Issue 1, p57-64. 8p.

Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials.

Authors: Streck, Joanna M. Ju-Whei Lee Walter, Angela Wangari et al.

Source: Cancer Epidemiology, Biomarkers & Prevention. Nov2023, Vol. 32 Issue 11, p1552-1557.